The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...

Analyst Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Alkermes (ALKS – Research Report) and keeping the price target at ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which ...

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Alkermes (ALKS – Research Report) yesterday and set a price target of ...

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.9%. Looking ahead, revenue ...

Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago. These figures are ...

Alkermes PLC (ALKS) reports robust revenue growth driven by Vivitrol and Lybalvi, while navigating market challenges and ...

Alkermes plc (NASDAQ:ALKS – Free Report) – Stock analysts at Leerink Partnrs dropped their FY2024 earnings per share ...

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, ...

These pharmaceutical stocks have attractive dividends and valuation upside.

Alkermes Plc (ALKS)报告了2024年第三季度强劲的财务业绩,总收入达到3.781亿美元,同比增长18%。增长主要由公司强大的专有产品组合驱动,包括VIVITROL、ARISTADA和LYBALVI。随着Alkermes为2025年做准备,公司将重点放在产生显著现金流和盈利能力上,战略重点是专有产品和推进ALKS 2680临床项目。

周四，金融服务公司Stifel调整了对Alkermes (NASDAQ: ALKS)股票的展望，将目标价从28.00美元下调至25.00美元，同时维持对该股票的持有评级。此次调整是在公司发布第三季度财报后做出的，财报结果喜忧参半。